Investigational drug · Phase 3
Bimatoprost Implant System
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cataract, Glaucoma, Ocular Hypertension.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "Bimatoprost Implant System"
First trial start
2023
Oct 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bimatoprost Implant System", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cataract
- Glaucoma
- Ocular Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Bimatoprost Implant System" as an intervention, largest first.
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)Pivotal-lookingRecruiting
SpyGlass Pharma, Inc.Industry
NCT07218783 · 400 participants (planned) · Start Oct 15, 2025 · Primary completion Mar 31, 2029
Drug: Bimatoprost Implant System; Timolol Maleate Ophthalmic Solution, 0.5% · For: Cataract; Glaucoma; Ocular Hypertension
Sites: Houston, Texas
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)Pivotal-lookingRecruiting
SpyGlass Pharma, Inc.Industry
NCT07218796 · 400 participants (planned) · Start Oct 28, 2025 · Primary completion May 31, 2029
Drug: Bimatoprost Implant System; Timolol Maleate Ophthalmic Solution, 0.5% · For: Cataract; Glaucoma; Ocular Hypertension
Sites: San Antonio, Texas
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic SolutionPivotal-lookingActive, not recruiting
SpyGlass Pharma, Inc.Industry
NCT06120842 · 201 participants · Start Oct 13, 2023 · Primary completion Jan 31, 2025
Drug: Bimatoprost Implant System (High Dose); Bimatoprost Implant System (Low Dose) and 1 more · For: Cataract; Glaucoma; Ocular Hypertension
Sites: Glendale, Arizona
SpyGlass Pharma, Inc.Industry
NCT07641296 · 24 participants (planned) · Start Jul 31, 2026 · Primary completion Feb 28, 2027
Drug: BIM-DRS Low Dose; BIM-DRS High Dose · For: Glaucoma; Ocular Hypertension
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.